How effective is ivonib in treating leukemia?

Ivosidenib is an inhibitor of isocitrate dehydrogenase -1 (IDH1) indicated for the treatment of acute myeloid leukemia (AML) in patients with predisposing IDH1 mutations as detected by FDA approved tests ).

Methods:In a phase 3 trial, we randomly assigned patients with newly diagnosed IDH1-mutated acute myeloid leukemia, who were ineligible for intensive induction chemotherapy, to receive oral ivosidenib(500 mg, once daily)and subcutaneous or intravenous azacitidine(75 mg/m2body surface area, span>28during 7days)or receiving matching placebo and azacitidine. The primary endpoint is event-free survival, defined as the time from randomization to treatment failure(i.e., the patient does not have complete remission at week 24< span>), relapse after remission, or death from any cause(whichever occurs first)time.

Results:The intention-to-treat population included146 patients:72 Examples are the avonib-azacitidine group, and 74cases are the placebo-azacitidine group. At a median follow-up of 12.4 months, event-free survival was significantly longer in the azacitidine group than in the placebo group. an>Azacitidine group(The hazard ratio for treatment failure, relapse into remission, or death was0.33;95%confidence interval[CI], 0.16 to 0.69; P = 0.002). The estimated probability of a patient remaining event-free at 12 months was 37% and 12% in the placebo-azacitidine group. The median overall survival was 24.0 months for ivonib and azacitidine and 7.9 months for placebo and azacitidine(The hazard ratio for death was . Common adverse events grade 3 or higher include febrile neutropenia(ivitinib 28% in the and azacitidine group, 34%) in the placebo and azacitidine group, and neutropenia The incidence of any grade bleeding event was 41% and 29% respectively. The rate of any grade infection was 28% in the ivosidenib and azacitidine group and 49% in the placebo and azacitidine group. Differentiation syndrome of any grade occurred in 14% of patients who received ivonib and azacitidine and in 8% of patients who received placebo and azacitidine.

Conclusion:Avosidenib and azacitidine demonstrated significant clinical benefit compared with placebo and azacitidine in this difficult-to-treat population. Compared with the placebo-azacitidine group, the incidence of febrile neutropenia and infection was lower in the ivosidenib-azacitidine group, while the incidence of neutropenia and bleeding was higher in the ivosidenib-azacitidine group. If you want to get more high-quality information, you can contact Yaodede. Yaode will do its best to learn more about high-quality overseas drugs for you.